Platelets News and Research RSS Feed - Platelets News and Research

Rapid-deployment plasma protocol helps treat trauma victims faster in the ER

Rapid-deployment plasma protocol helps treat trauma victims faster in the ER

Traumatic injury is the leading cause of death among people under age 45, but if trauma physicians could deliver plasma to these injury victims within minutes of their arrival in the emergency room, more of them would stand a better chance of survival. [More]
Verax Biomedical obtains FDA clearance to expand use of Verax Platelet PGD test

Verax Biomedical obtains FDA clearance to expand use of Verax Platelet PGD test

Verax Biomedical today announced that the company has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The new FDA clearance makes the Verax Platelet PGD test the only rapid test on the market cleared by the FDA to check every commonly distributed platelet type in the United States. [More]
Cardiology researchers uncover new evidence that relates to increased risk of stroke

Cardiology researchers uncover new evidence that relates to increased risk of stroke

Cardiology researchers at The Queen Elizabeth Hospital have uncovered new evidence that relates to patients with new onset atrial fibrillation (AF) and their increased risk of stroke. [More]
Regular use of aspirin may slow the progression of early emphysema, new research shows

Regular use of aspirin may slow the progression of early emphysema, new research shows

Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference. [More]
Quest Diagnostics launches genomic test service that aids in diagnosis for myeloid neoplasms

Quest Diagnostics launches genomic test service that aids in diagnosis for myeloid neoplasms

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that includes acute myeloid leukemia (AML), the most common form of adult acute leukemia, as well as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs). [More]
Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association. [More]
Use of fresh whole blood from single donors may reduce complications in pediatric heart surgery patients

Use of fresh whole blood from single donors may reduce complications in pediatric heart surgery patients

Using fresh whole blood from single donors is better than using component blood from multiple donors in pediatric heart surgery patients, according to an article in the May 2015 issue of The Annals of Thoracic Surgery. [More]
ITIM-containing receptor crucial for development of acute myeloid leukemia

ITIM-containing receptor crucial for development of acute myeloid leukemia

UT Southwestern Medical Center scientists have discovered that a certain class of receptors that inhibit immune response are crucial for the development of acute myeloid leukemia (AML), the most common acute leukemia affecting adults. [More]
First patient enrolled in CryoLife's PerClot IDE clinical trial

First patient enrolled in CryoLife's PerClot IDE clinical trial

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the enrollment of the first patient in its PerClot Investigational Device Exemption (IDE) clinical trial, the Company's pivotal clinical trial to gain approval to commercialize PerClot in the U.S. [More]
Researchers describe natural mechanism that helps repair lesions in teeth

Researchers describe natural mechanism that helps repair lesions in teeth

Researchers at Inserm and Paris Descartes University have just taken an important step in research on stem cells and dental repair. They have managed to isolate dental stem cell lines and to describe the natural mechanism by which they repair lesions in the teeth. This fundamental discovery will make it possible to initiate unprecedented therapeutic strategies to mobilise the resident dental stem cells and magnify their natural capacity for repair. [More]
MGH researchers find probable mechanism associated with risk of developing serious diseases

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream. [More]
Newly discovered bodily process may explain fetal brain bleeds

Newly discovered bodily process may explain fetal brain bleeds

A newly discovered bodily process in mice may explain why some human fetuses who have different antigens than their mothers suffer life-threatening brain bleeds, according to a new study. [More]
New anti-clotting therapy no better than established anticoagulants

New anti-clotting therapy no better than established anticoagulants

A novel therapy that would allow doctors to turn the body's blood-clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing angioplasty but was associated with higher rates of moderate to severe bleeding, according to an analysis of data from a terminated Phase III trial presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
NYU Langone Medical Center researchers find that air pollution may pose significant stroke risk

NYU Langone Medical Center researchers find that air pollution may pose significant stroke risk

Air pollution has been linked to a dangerous narrowing of neck arteries that occurs prior to strokes, according to researchers at NYU Langone Medical Center. [More]
Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera. [More]
New injectable polymer could strengthen blood clots

New injectable polymer could strengthen blood clots

Most military battlefield casualties die before ever reaching a surgical hospital. Of those soldiers who might potentially survive, most die from uncontrolled bleeding. [More]
People who exhibit resistance to aspirin may be at risk of more severe strokes

People who exhibit resistance to aspirin may be at risk of more severe strokes

People who exhibit a resistance to aspirin may be more likely to have more severe strokes than people who still respond to the drug, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015. [More]
Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers at the UNC School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases. [More]
Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix™, a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores). [More]
Study compares two different methods of blood transfusion in trauma care

Study compares two different methods of blood transfusion in trauma care

The University of Maryland School of Medicine is part of a new nationwide, multi-site study that may help save hundreds of lives among trauma patients with major bleeding. The study, which was published earlier this month in JAMA, compared two different methods of blood transfusion, and found that one approach gave patients a significantly better chance of survival within the first 24 hours. [More]
Advertisement